This study took advantage of the earlier finding that FTY720, an FDA-approved drug that targets S1P1 for the treatment of multiple sclerosis, inhibits TRPM7 in its unphosphorylated prodrug form, but not in its phosphorylated form. Here, S1PR1 is linked to multiple sclerosis.